Levofloxacin
Phase 1Completed 0 views this week 0 watching💤 Quiet
Interest: 29/100
29
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedAbout Levofloxacin
Levofloxacin is a phase 1 stage product being developed by Johnson & Johnson for HIV Infections. The current trial status is completed. This product is registered under clinical trial identifier NCT00002249. Target conditions include HIV Infections.
What happened to similar drugs?
20 of 20 similar drugs in HIV Infections were approved
Approved (20) Terminated (3) Active (0)
Hype Score Breakdown
Clinical
6
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (18)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00002249 | Phase 1 | Completed |
| NCT00210886 | Phase 3 | Completed |
| NCT00645437 | Phase 1 | Completed |
| NCT00236652 | Phase 3 | Completed |
| NCT00044473 | Phase 3 | Completed |
| NCT00236522 | Phase 3 | Completed |
| NCT00034736 | Phase 3 | Completed |
| NCT00236821 | Phase 3 | Completed |
| NCT00236808 | Phase 3 | Completed |
| NCT00249197 | Phase 3 | Completed |
| NCT00269932 | Phase 3 | Completed |
| NCT00249210 | Phase 3 | Completed |
| NCT00258089 | Phase 3 | Completed |
| NCT00258102 | Phase 3 | Completed |
| NCT00257062 | Phase 3 | Completed |
| NCT00257036 | Phase 2/3 | Completed |
| NCT00257049 | Phase 2/3 | Completed |
| NCT00257140 | Phase 2/3 | Completed |
Competing Products
20 competing products in HIV Infections